Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Up 6.9% in April: Crecon Report
June 9, 2015
- Nesina Similar to Placebo in CV Event Risk in Patients on ACE Inhibitors: Takeda
June 9, 2015
- Once-Weekly Omarigliptin Reduces HbA1c Levels as Add-on Treatment in PIII Study in Japanese Patents: MSD
June 9, 2015
- Highlights of FY2014 Earnings - Part 4: Overseas Sales Top 4 Trillion Yen; Fate of Drug Makers Will Depend on New Global Products
June 9, 2015
- Highlights of FY2014 Earnings - Part 3: New Cancer Drugs Off to Strong Start
June 8, 2015
- Lilly Hopes Alzheimer’s Drug Solanezumab Will Be World’s First-in-Class
June 5, 2015
- Japan Should Open Up AMED’s Achievements Globally: Lilly Execs
June 5, 2015
- Lilly Japan Plans Excursion to Local Cities in Quest for Novel Drug Seeds
June 5, 2015
- No. of Hospitals with Less than 20% Generic Prescription Rate Down Sharply: Survey
June 5, 2015
- Highlights of FY2014 Earnings - Part 2: Sales of 42 Major Long-Listed Products Sag Nearly 20%
June 5, 2015
- Aspen Japan Commences Operations in Japan
June 5, 2015
- Takecab Ranks 1st for 4th Month Running in GP, HP Markets in April: Anterio Ranking
June 4, 2015
- Takeda to Set Up Global Vaccine Business Hub in US
June 4, 2015
- Highlights of FY2014 Earnings - Part 1: 35 Listed Drug Makers See Downtrend in Profits Despite 3% Sales Uptick
June 4, 2015
- MSD Transfers Marketing Rights for Claritin to Bayer Yakuhin
June 3, 2015
- Astellas, Anokion Join Hands on Immune Tolerance Therapeutics
June 3, 2015
- Merck Serono Names CFO Koji Okamoto as New President
June 2, 2015
- Former Merck Serono President Feliciano Becomes AbbVie G.K.’s New President
June 2, 2015
- Pfizer, Merck Serono Initiate Copromotion for Xalkori
June 2, 2015
- 14-Day Prescription Limit Lifted for Efient: Daiichi Sankyo
June 2, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…